Noninvasive tests for liver fibrosis

Sandeep Mukherjea, Michael Floyd Sorrell

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The field of noninvasive markers for the assessment of hepatic fibrosis has seen tremendous growth in the last two decades. Surrogate markers are gradually being substituted for biomarkers that reflect the complex balance between synthesis and degradation of the extracellular matrix. Coupled with these promising tests are artificial intelligence networks devised by sophisticated statistical instruments that incorporate a battery of laboratory tests and biomarkers with imaging modalities. Recently, gene identification and protein analysis have shown promise in identifying selected patients with mild or advanced fibrosis. Despite such progress, an important limitation of these tests is the frequent inability to detect mild fibrosis although patients at the end of the histological spectrum (i.e., advanced fibrosis or cirrhosis) are readily identified. With time, it is anticipated a combination of serological and radiological tests together with genetic and proteomic investigations will provide accurate assessment of fibrosis in a cost-effective and timely manner.

Original languageEnglish (US)
Pages (from-to)337-347
Number of pages11
JournalSeminars in liver disease
Volume26
Issue number4
DOIs
StatePublished - Nov 1 2006

Fingerprint

Liver Cirrhosis
Fibrosis
Biomarkers
Artificial Intelligence
Serologic Tests
Proteomics
Extracellular Matrix
Costs and Cost Analysis
Liver
Growth
Proteins

Keywords

  • Fibrosis
  • Noninvasive tests
  • Radiological markers
  • Serological markers

ASJC Scopus subject areas

  • Hepatology

Cite this

Noninvasive tests for liver fibrosis. / Mukherjea, Sandeep; Sorrell, Michael Floyd.

In: Seminars in liver disease, Vol. 26, No. 4, 01.11.2006, p. 337-347.

Research output: Contribution to journalReview article

Mukherjea, Sandeep ; Sorrell, Michael Floyd. / Noninvasive tests for liver fibrosis. In: Seminars in liver disease. 2006 ; Vol. 26, No. 4. pp. 337-347.
@article{114836428b924dda8cf07289f6cbb541,
title = "Noninvasive tests for liver fibrosis",
abstract = "The field of noninvasive markers for the assessment of hepatic fibrosis has seen tremendous growth in the last two decades. Surrogate markers are gradually being substituted for biomarkers that reflect the complex balance between synthesis and degradation of the extracellular matrix. Coupled with these promising tests are artificial intelligence networks devised by sophisticated statistical instruments that incorporate a battery of laboratory tests and biomarkers with imaging modalities. Recently, gene identification and protein analysis have shown promise in identifying selected patients with mild or advanced fibrosis. Despite such progress, an important limitation of these tests is the frequent inability to detect mild fibrosis although patients at the end of the histological spectrum (i.e., advanced fibrosis or cirrhosis) are readily identified. With time, it is anticipated a combination of serological and radiological tests together with genetic and proteomic investigations will provide accurate assessment of fibrosis in a cost-effective and timely manner.",
keywords = "Fibrosis, Noninvasive tests, Radiological markers, Serological markers",
author = "Sandeep Mukherjea and Sorrell, {Michael Floyd}",
year = "2006",
month = "11",
day = "1",
doi = "10.1055/s-2006-951598",
language = "English (US)",
volume = "26",
pages = "337--347",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Noninvasive tests for liver fibrosis

AU - Mukherjea, Sandeep

AU - Sorrell, Michael Floyd

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The field of noninvasive markers for the assessment of hepatic fibrosis has seen tremendous growth in the last two decades. Surrogate markers are gradually being substituted for biomarkers that reflect the complex balance between synthesis and degradation of the extracellular matrix. Coupled with these promising tests are artificial intelligence networks devised by sophisticated statistical instruments that incorporate a battery of laboratory tests and biomarkers with imaging modalities. Recently, gene identification and protein analysis have shown promise in identifying selected patients with mild or advanced fibrosis. Despite such progress, an important limitation of these tests is the frequent inability to detect mild fibrosis although patients at the end of the histological spectrum (i.e., advanced fibrosis or cirrhosis) are readily identified. With time, it is anticipated a combination of serological and radiological tests together with genetic and proteomic investigations will provide accurate assessment of fibrosis in a cost-effective and timely manner.

AB - The field of noninvasive markers for the assessment of hepatic fibrosis has seen tremendous growth in the last two decades. Surrogate markers are gradually being substituted for biomarkers that reflect the complex balance between synthesis and degradation of the extracellular matrix. Coupled with these promising tests are artificial intelligence networks devised by sophisticated statistical instruments that incorporate a battery of laboratory tests and biomarkers with imaging modalities. Recently, gene identification and protein analysis have shown promise in identifying selected patients with mild or advanced fibrosis. Despite such progress, an important limitation of these tests is the frequent inability to detect mild fibrosis although patients at the end of the histological spectrum (i.e., advanced fibrosis or cirrhosis) are readily identified. With time, it is anticipated a combination of serological and radiological tests together with genetic and proteomic investigations will provide accurate assessment of fibrosis in a cost-effective and timely manner.

KW - Fibrosis

KW - Noninvasive tests

KW - Radiological markers

KW - Serological markers

UR - http://www.scopus.com/inward/record.url?scp=33750366551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750366551&partnerID=8YFLogxK

U2 - 10.1055/s-2006-951598

DO - 10.1055/s-2006-951598

M3 - Review article

VL - 26

SP - 337

EP - 347

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -